Skip to main navigation Skip to search Skip to main content

Paramyxoviruses: Pathogenesis, Vaccines, Antivirals, and Prototypes for Pandemic Preparedness

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

The Paramyxoviridae family includes established human pathogens such as measles virus, mumps virus, and the human parainfluenza viruses; highly lethal zoonotic pathogens such as Nipah virus; and a number of recently identified agents, such as Sosuga virus, which remain poorly understood. The high human-to-human transmission rate of paramyxoviruses such as measles virus, high case fatality rate associated with other family members such as Nipah virus, and the existence of poorly characterized zoonotic pathogens raise concern that known and unknown paramyxoviruses have significant pandemic potential. In this review, the general life cycle, taxonomic relationships, and viral pathogenesis are described for paramyxoviruses that cause both systemic and respiratory system-restricted infections. Next, key gaps in critical areas are presented, following detailed conversations with subject matter experts and based on the current literature. Finally, we present an assessment of potential prototype pathogen candidates that could be used as models to study this important virus family, including assessment of the strengths and weaknesses of each potential prototype.

Original languageEnglish
Pages (from-to)S390-S397
JournalJournal of Infectious Diseases
Volume228
DOIs
StatePublished - Oct 15 2023

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Funding

Financial support. This work was supported by the National Institutes of Health (grant numbers 5R01 AI40758 and 1R01 AI051517 to R. E. D.) and the Coalition for Epidemic Preparedness Innovations and the Henry Hillman Family Foundation (to W. P. D.). Supplement sponsorship. This article appears as part of the supplement “Pandemic Preparedness at NIAID: Prototype Pathogen Approach to Accelerate Medical Countermeasures—Vaccines and Monoclonal Antibodies,” sponsored by the National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD.

FundersFunder number
Henry Hillman Family Foundation
National Institutes of Health (NIH)1R01 AI051517, 5R01 AI40758
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...
Coalition for Epidemic Preparedness Innovations

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • pandemic preparedness
    • paramyxovirus
    • prototype pathogens
    • zoonosis

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Paramyxoviruses: Pathogenesis, Vaccines, Antivirals, and Prototypes for Pandemic Preparedness'. Together they form a unique fingerprint.

    Cite this